Pharmacological-toxicological expert report. CAELYX. (Stealth liposomal doxorubicin HCl).
Working
P K
PK
SEQUUS Pharmaceuticals, Inc., Menlo Park, California, USA.
Dayan
A D
AD
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D016466:CHO Cells / Q000187:drug effects; D006224:Cricetinae; D003412:Cricetulus; D004195:Disease Models, Animal; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D016503:Drug Delivery Systems; D005314:Embryonic and Fetal Development / Q000187:drug effects; D006801:Humans; D007275:Injections, Intravenous; D008081:Liposomes; D051379:Mice; D009152:Mutagenicity Tests; D009374:Neoplasms, Experimental / Q000188:drug therapy; D010865:Pilot Projects; D011817:Rabbits; D051381:Rats; D014018:Tissue Distribution
D000903:Antibiotics, Antineoplastic; D008081:Liposomes; D004317:Doxorubicin